WE ARE CONTINUOUSLY INNOVATING …
In order to provide technologies that answer current unmet needs in oral formulation, Skyepharma launched an Innovation pipeline. The research programs in collaboration with international universities and research institutes address issues such as bioavailability, precision delivery and long extended release. The developed technologies should strengthen company IP portfolio and offer to our customers oral solutions that fully match their Target Product Profiles.
GEOBIOLOGICS PROGRAM
Biologicals (proteins, peptides and therapeutic antibodies) have been successfully developed for the treatment of diabetes, metabolic diseases, rheumatoid arthritis, inflammatory bowel disease and cancer. Although the oral administration of those biomolecules makes sense, available treatments are predominantly intravenous and oral formulation remains poorly clinically explored.
Skyepharma is collaborating with University of Bordeaux to develop a unique formulation platform derived from its patented Geoclock® technology (Tab-In-Tab) to allow local or systemic delivery of biologics. Open to partnership for pharmaceutical/biotech companies developing biomolecules.
NANOMICS AND NANOFACT
Most of new chemical entities display low solubility in biological fluids (class II and IV molecules according to Biopharmaceutics Classification System) leading to poor bioavailability.
Skyepharma is collaborating with University of Lyon on the development of nanoparticles-containing tablets with the objective to reduce food effect and metabolization while increasing drug delivery at pharmacologic site (local or systemic) for BCS II/IV molecules. The process relying on high pressure homogenization is solvent-free and fully scalable. Skyepharma also entered Nanofact consortium for the development of continuous manufacturing equipment of nanoparticles. Open to partnership for pharmaceutical/biotech companies facing bioavailability issues.
MUCOTABS PROGRAM
Delivery of precision and long-lasting release is needed to optimize efficacy of oral treatments.
MucoTabS innovation program in collaboration with university of Lyon aims at developing a technology platform enabling the targeting of the different GI tract regions (stomach, small intestine, colon) and promoting muco-adhesion to increase local residence time of API. This will allow local or systemic release of the Active Ingredient over a period of 24h or more which should reduce dosage strength and minimize side effects. Open to partnership for pharmaceutical/biotech companies needing extended release of their active ingredient.
GEOCOLON PROGRAM
Colon-targeting is of particular interest to reduce off-target side effects and increase local delivery of active drug for inflammatory diseases (rheumatoid arthiris, inflammatory bowel disease). It is also a promising approach for emerging therapeutic targets such as microbiome, enteric immune and lymphatic systems.
Skyepharma is collaborating with University of Lille to develop a formulation enabling the release of the active ingredient in the presence of colonic bacteria. Open to partnership for pharmaceutical/biotech companies having colon-located therapeutic targets.